(VIANEWS) – Shares of Pacific Biosciences of California (NASDAQ: PACB) dropped 8.56% to $5.64 at 14:49 EST on Tuesday, after three sequential sessions in a row of gains. NASDAQ is rising 0.33% to $12,171.42, after three sequential sessions in a row of gains. This seems, as yet, a somewhat bullish trend exchanging session today.

Pacific Biosciences of California’s last close was $6.17, 83.03% under its 52-week high of $36.36.

Volume

Today’s last reported volume for Pacific Biosciences of California is 4721756 which is 27.25% below its average volume of 6490666.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 17% for the current quarter and 30.3% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 57.1% and a negative 500%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 32.7%, now sitting on 130.51M for the twelve trailing months.

Volatility

Pacific Biosciences of California’s last week, last month’s, and last quarter’s current intraday variation average was a positive 2.96%, a negative 0.78%, and a positive 5.81%, respectively.

Pacific Biosciences of California’s highest amplitude of average volatility was 3.25% (last week), 7.16% (last month), and 5.81% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be oversold (<=20).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $5.64 at 14:49 EST, way below its 52-week high of $36.36 and way higher than its 52-week low of $4.51.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s worth is way under its 50-day moving average of $7.39 and way under its 200-day moving average of $17.48.

More news about Pacific Biosciences of California (PACB).

LEAVE A REPLY

Please enter your comment!
Please enter your name here